| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301093 | 华兰股份 | 80.77 | 1.87% | 6.14万 | 4.92亿 | | 300639 | 凯普生物 | 8.81 | 1.26% | 179.34万 | 16.54亿 | | 600807 | 济高发展 | 3.58 | 0.85% | 36.50万 | 1.30亿 | | 002223 | 鱼跃医疗 | 41.50 | 0.61% | 11.61万 | 4.81亿 | | 002382 | 蓝帆医疗 | 6.06 | 0.33% | 20.18万 | 1.21亿 | | 301290 | 东星医疗 | 28.61 | 0.00% | 2.36万 | 6809.51万 | | 688253 | 英诺特 | 36.77 | -0.11% | 3.60万 | 1.31亿 | | 688013 | 天臣医疗 | 43.42 | -0.37% | 1.37万 | 5955.36万 | | 002086 | 东方海洋 | 2.28 ...

Market Overview - The three major indices showed mixed performance, with the Shanghai Composite Index rising by 0.49% to 4160.01, the Shenzhen Component Index increasing by 0.09% to 14342.74, and the ChiNext Index declining by 0.37% to 3330.39 [1][2]. Sector Performance - Precious metals, industrial metals, and petrochemicals sectors performed strongly, while solar energy, pharmaceuticals, and aerospace sectors experienced fluctuations [2]. - The basic metals sector saw significant gains, with copper and aluminum industries leading the rise, as multiple stocks hit the daily limit up [6]. Stock Highlights - Notable stocks included China National Offshore Oil Corporation, China Petroleum, and China Unicom, which showed strong performance [4]. - The aluminum futures market saw a rise of over 4%, with the main contract reported at 25345 yuan/ton [8]. Biotechnology Sector - The biotechnology sector faced declines, with several companies such as Zhijiang Biology and Baipusais losing over 9% [10][11]. Solar Energy Sector - The solar energy sector faced downward adjustments, with companies like High Measurement and Maiwei experiencing drops exceeding 6% [11].

Market Overview - A-shares showed mixed performance with the Shanghai Composite Index rising while the ChiNext Index experienced a decline of over 1% at one point [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.91 trillion yuan, an increase of 39.3 billion yuan compared to the previous trading day [1] - More than 3,500 stocks in the market declined, indicating a bearish sentiment overall [1] Sector Performance - Resource stocks saw a collective surge, with precious metals and oil & gas sectors leading the gains [3] - Notable performances included China Gold with four consecutive trading limit ups, Hunan Gold with three, and Sichuan Gold achieving six limit ups in ten days [3] - China National Offshore Oil Corporation (CNOOC) rose over 7%, reaching a historical high, while PetroChina and other related stocks also saw significant gains [3] - The dispersed dye concept stocks performed well, with Zhejiang Longsheng, Runtou Co., and Yabong Co. hitting their trading limits [3] - Storage chip concept stocks were active, with Puran Co. rising over 15% to set a new historical high, and Qipai Technology hitting the 20% limit up [3] Declining Sectors - The virus prevention concept stocks collectively fell, with Zhijiang Bio dropping over 9% [4] - At the close, the Shanghai Composite Index rose by 0.49%, the Shenzhen Component Index increased by 0.09%, while the ChiNext Index fell by 0.37% [4]

Group 1 - The three major indices showed mixed performance, with the Shanghai Composite Index rising while the ChiNext Index experienced a decline of over 1% at one point [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.91 trillion yuan, an increase of 39.3 billion yuan compared to the previous trading day [1] - Over 3,500 stocks in the market declined, indicating a broader market weakness despite some sectors performing well [1] Group 2 - Resource stocks saw a collective surge, with precious metals and oil & gas sectors leading the gains; notable performers included China Gold with four consecutive trading limits and China National Offshore Oil Corporation rising over 7% to set a new historical high [1] - The disperse dye concept stocks also performed strongly, with Zhejiang Longsheng, Runtu Co., and Yabang Investment hitting their trading limits [1] - Storage chip concept stocks were active, with Puran Co. rising over 15% to reach a new historical high, and Gipai Technology hitting the 20% trading limit [1] Group 3 - In contrast, the virus prevention concept stocks collectively fell, with Zhijiang Biology dropping over 9% [1] - At the close, the Shanghai Composite Index rose by 0.49%, the Shenzhen Component Index increased by 0.09%, while the ChiNext Index fell by 0.37% [1]

【导读】印度尼帕病毒疫情引关注，相关概念股大涨，多家公司紧急回应 据悉，尼帕病毒感染潜伏期为3至14天，初期症状与流感相似，易出现误诊。这也意味着，早期精准检 测不仅能为临床干预争取时间，也是落实国境检疫、疫情溯源的核心环节。 随着尼帕病毒疫情持续发酵，市场对病毒防治、体外诊断等相关概念股的关注明显升温。截至1月27日 收盘，相关板块个股集体走强，凯普生物、达安基因斩获两连板；拓新药业、利德曼、特一药业等个股 涨幅居前。 | 凯普生物 | 8.70 | 20.00% | 1.45 | | --- | --- | --- | --- | | 300639 | | | | | ■正米 (天2板 入气龙头- 激电人 2020年半年频型示公司目主研发的 | | | | | 新型冠状病毒(2019-nCaV)核酸检测试刊盒(艾光PCR法)以新型冠状 ... | | | | | 达安惠因 | 7.71 | 9.99% | 0.70 | | 002030 @ | | | | | ■更新 2天2板 人气息头三 周期人用 多种药毒检测服务 | | | | | 拓新药业 | | 34.37 7.98% | 2.54 | | 30 ...

【导读】印度尼帕病毒疫情引关注，相关概念股大涨，多家公司紧急回应 据央视新闻报道，尼帕病毒病主要通过直接接触感染的动物、病人及污染物传播，病毒环境存活力弱，一般民众接触感染机会较少。本 次印度暴发的尼帕病毒病疫情，主要发生在西孟加拉邦，该地区与我国没有领土接壤。 综合研判，此次印度尼帕病毒病疫情对我国产生的影响相对较小。目前，我国尚未发现尼帕病毒病病例。但也存在一定境外输入风险， 需加强防范。 据悉，尼帕病毒感染潜伏期为3至14天，初期症状与流感相似，易出现误诊。这也意味着，早期精准检测不仅能为临床干预争取时间， 也是落实国境检疫、疫情溯源的核心环节。 随着尼帕病毒疫情持续发酵，市场对病毒防治、体外诊断等相关概念股的关注明显升温。截至1月27日收盘，相关板块个股集体走强， 凯普生物（300639）、达安基因（002030）斩获两连板；拓新药业（301089）、利德曼（300289）、特一药业（002728）等个股涨幅居 前。 | 凯普生物 | 8.70 | 20.00% | 1.45 | | --- | --- | --- | --- | | 300639 倍 | | | | | ■正制 2天2板 入气龙头一 ...

Group 1 - The recent outbreak of Nipah virus disease in West Bengal, India, has raised significant concern, with 5 confirmed cases reported, including healthcare workers, and nearly 100 individuals under home quarantine [1] - The impact of the Nipah virus outbreak on China is relatively minor, with no cases reported in the country, although there is a risk of imported cases that necessitates enhanced preventive measures [1][2] - Nipah virus has been known for over 20 years, with its first outbreak occurring in Malaysia in 1998, and it primarily affects South Asia and Southeast Asia [1][2] Group 2 - The Nipah virus primarily damages the central nervous system (90%) and respiratory system (62%), with a high fatality rate ranging from 40% to 75% [2] - Experts indicate that the Nipah virus has a low basic reproduction number (R₀) compared to influenza or COVID-19, and there have been no reports of large-scale airborne transmission [4] - Current antiviral treatments for Nipah virus are limited, with no approved drugs or vaccines available, although Ribavirin may be effective for treating Nipah virus encephalitis [4][5] Group 3 - Recent research has shown that VV116 has antiviral activity against Nipah virus in vitro and can improve survival rates in mouse models, indicating potential for treatment [4][5] - Several companies have reported possessing Nipah virus testing technology or products, but they have not yet achieved significant revenue from these offerings [6] - The most common testing method for Nipah virus is nucleic acid testing, and public health departments are equipped to handle such testing, which is deemed sufficient for current needs [6]

Group 1 - The Nipah virus outbreak in West Bengal, India has confirmed 5 cases with nearly 100 people under observation, prompting neighboring countries like Thailand and Nepal to enhance health screening for travelers from India [1] - The World Health Organization (WHO) classifies the Nipah virus as a high-priority regional threat due to its high mortality rate of 40%-70% and the absence of approved vaccines or treatments [4][11] - The research team from Wuhan Institute of Virology has published findings indicating that the oral nucleoside drug VV116 shows significant antiviral activity against the Nipah virus, providing new hope for treatment [2][8] Group 2 - VV116, developed by Wangshan Wangshui and Junshi Biosciences, has shown potential against various RNA viruses, including the Nipah virus, and has been approved for COVID-19 treatment in China and Uzbekistan [7][8] - Following the announcement of VV116's efficacy against the Nipah virus, shares of Wangshan Wangshui surged by 10.9%, reaching a new high since its listing in November 2025 [4][5] - The market response to the Nipah virus outbreak has led to significant stock price increases for several companies involved in diagnostic testing, with companies like Kaipu Biological and Da'an Gene reporting substantial gains [12][13]

Core Viewpoint - The article highlights the outbreak of Nipah virus in West Bengal, India, and emphasizes the critical role of rapid and accurate testing in epidemic prevention and monitoring, given the virus's high mortality rate of 40%-75% and the absence of effective vaccines or treatments [3]. Group 1: Industry Response - Companies such as Capbio, Shuoshi Bio, and Zhongke Shengyi have quickly responded to the Nipah virus outbreak by providing testing kits to aid in epidemic monitoring and prevention [4]. - The Nipah virus is classified as a newly emerging zoonotic virus, causing severe diseases characterized by encephalitis or respiratory illnesses in infected individuals [6]. Group 2: Product Offerings - Capbio offers a range of Nipah virus nucleic acid testing kits using fluorescence PCR methods, with various packaging options available [11]. - The testing kits include specifications for different sample types such as serum, plasma, throat swabs, whole blood, urine, and viral cultures, with a detection limit of 500 copies/mL and a report time of 70 minutes [18].

凯普生物20cm涨停，智飞生物、万孚生物涨超10%，之江生物、华兰疫苗此前涨停，康希诺、硕世生 物、科华生物涨幅居前。 (本文来自第一财经) ...